Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Preclinical Development of Personalized Functional Markers for Deep Brain Stimulation

Project description

Advancing personalised deep brain stimulation treatment

Deep brain stimulation (DBS) has been employed to treat neurological and neuropsychiatric disorders in more than 300 000 patients worldwide, but its effectiveness varies. The research project DirectThalamus has found a new neural oscillation near DBS targets that may improve localisation and reduce non-responder rates. The ERC-funded optimizeDBS project aims to support preclinical work to refine detection methods and assess this approach in larger patient groups. The project will complete preclinical work and prepare for a clinical trial to integrate its approach into clinical practice. By combining advanced neuroscience with medicine and promoting collaboration among researchers, clinicians and medical device specialists, the project seeks to enhance therapy effectiveness and advance personalised DBS treatment.

Objective

Deep brain stimulation (DBS) is used to treat neurological and neuropsychiatric disorders. To date, DBS devices have been implanted in more than 300,000 patients worldwide. However, the efficacy of DBS therapy varies across patients, leaving a substantial number of patients without significant symptom alleviation. Optimizing therapeutic outcomes is highly desirable for the patients’ well-being as well as to reduce socio-economic burden of untreated disorders. One of the major impeding obstacles is the difficulty to precisely localize DBS targets in individual patient brains. Despite research into alternatives, the need for optimizing target localization for DBS remains unmet.

The recent discovery of a hitherto unreported neural oscillation, enabled by my previous ERC Starting Grant DirectThalamus, is a promising solution to these challenges. The novel oscillation is spatially confined to the proximity of established DBS targets and could thus be used as a functional marker to improve localization and reduce non-responder rates. Funding from the ERC Proof of Concept aims to support essential preclinical steps towards establishing a functional marker of DBS targets that is associated with superior clinical outcomes. Those include optimization of detection algorithms, exploration of alternative access routes to deep brain electrophysiology and evaluation of the functional marker in larger cohorts. The goal of the project is to finalize preclinical work and prepare the implementation and funding of a clinical trial with the goal to realize the approach in clinical routines.

By integrating cutting-edge neuroscience with medicine and fostering collaboration among researchers, clinicians and medical device specialists, the project aims to optimize therapy effectiveness, advance DBS technologies and pave the way for the next generation neuromodulation: personalized DBS treatment.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Net EU contribution
€ 150 000,00
Address
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)